Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
received:
30
05
2023
accepted:
21
03
2024
revised:
15
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
The role of the focal adhesion protein kindlin-3 as a tumor suppressor and its interaction mechanisms with extracellular matrix constitute a major field of investigation to better decipher tumor progression. Besides the well-described role of kindlin-3 in integrin activation, evidence regarding modulatory functions between melanoma cells and tumor microenvironment are lacking and data are needed to understand mechanisms driven by kindlin-3 inactivation. Here, we show that kindlin-3 inactivation through knockdown or somatic mutations increases BRAF
Identifiants
pubmed: 38570692
doi: 10.1038/s41388-024-03014-3
pii: 10.1038/s41388-024-03014-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. Eur J Cancer. 2020;126:141–58.
pubmed: 31928887
doi: 10.1016/j.ejca.2019.11.014
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. Eur J Cancer. 2020;126:159–77.
pubmed: 31866016
doi: 10.1016/j.ejca.2019.11.015
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–96.
doi: 10.1016/j.cell.2015.05.044
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248–60.
pubmed: 27480103
doi: 10.1016/S1470-2045(16)30122-X
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet Lond Engl. 2015;386:444–51.
doi: 10.1016/S0140-6736(15)60898-4
Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients With BRAF V600-Mutant Melanoma. J Clin Oncol J Am Soc Clin Oncol. 2022;40:4178–88.
doi: 10.1200/JCO.21.02659
Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:643–54.
pubmed: 33857412
doi: 10.1016/S1470-2045(21)00065-6
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl J Med. 2015;372:320–30.
pubmed: 25399552
doi: 10.1056/NEJMoa1412082
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N. Engl J Med. 2022;386:24–34.
pubmed: 34986285
pmcid: 9844513
doi: 10.1056/NEJMoa2109970
Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res J Am Assoc Cancer Res. 2014;20:1965–77.
doi: 10.1158/1078-0432.CCR-13-3122
Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer Oxf Engl. 1990 2015;51:2792–9.
Lim SY, Menzies AM, Rizos H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer. 2017;123:2118–29.
pubmed: 28543695
doi: 10.1002/cncr.30435
Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660–70.
pubmed: 35241833
pmcid: 9106900
doi: 10.1038/s41590-022-01141-1
Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015;135:508–15.
pubmed: 25148578
doi: 10.1038/jid.2014.366
Miraflor AP, de Abreu FB, Peterson JD, Turner SA, Amos CI, Tsongalis GJ, et al. Somatic mutation analysis in melanoma using targeted next generation sequencing. Exp Mol Pathol. 2017;103:172–7.
pubmed: 28822769
doi: 10.1016/j.yexmp.2017.08.006
Louveau B, Jouenne F, Têtu P, Sadoux A, Gruber A, Lopes E, et al. A melanoma-tailored next-generation sequencing panel coupled with a comprehensive analysis to improve routine melanoma genotyping. Target Oncol. 2020;15:759–71.
pubmed: 33151472
doi: 10.1007/s11523-020-00764-4
Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol J Eur Soc Med Oncol 2017;28:1380–7.
doi: 10.1093/annonc/mdx079
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, et al. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. J Invest Dermatol. 2018;138:58–67.
pubmed: 28843487
doi: 10.1016/j.jid.2017.07.839
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N. Engl J Med. 2018;378:731–9.
pubmed: 29466156
pmcid: 5857389
doi: 10.1056/NEJMoa1714448
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol Févr. 2020;21:271–82.
doi: 10.1016/S1470-2045(19)30691-6
Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, et al. Selective Oral MEK1/2 inhibitor pimasertib in metastatic melanoma: antitumor activity in a phase I, dose-escalation trial. Target Oncol. 2021;16:47–57.
pubmed: 33211315
doi: 10.1007/s11523-020-00767-1
Monaco KA, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, et al. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. Clin Cancer Res J Am Assoc Cancer Res. 2021;27:2061–73.
doi: 10.1158/1078-0432.CCR-20-2563
Louveau B, Resche-Rigon M, Lesimple T, Da Meda L, Pracht M, Baroudjian B, et al. Phase I-II open-label multicenter study of palbociclib + vemurafenib in BRAF V600MUT metastatic melanoma patients: uncovering CHEK2 as a major response mechanism. Clin Cancer Res J Am Assoc Cancer Res. 2021;27:3876–83.
doi: 10.1158/1078-0432.CCR-20-4050
Ascierto PA, Bechter O, Wolter P, Lebbe C, Elez E, Miller WH, et al. A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. J Clin Oncol. 2017;35:9518.
doi: 10.1200/JCO.2017.35.15_suppl.9518
Sussman TA, Wei W, Hobbs B, Diaz-Montero CM, Ni Y, Arbesman J, et al. A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness. J Clin Oncol. 2020;38:TPS10082.
doi: 10.1200/JCO.2020.38.15_suppl.TPS10082
Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236–50.
pubmed: 31404607
doi: 10.1016/j.semcancer.2019.08.002
Liu D, Yang X, Wu X. Tumor immune microenvironment characterization identifies prognosis and immunotherapy-related gene signatures in melanoma. Front Immunol. 2021;12:663495.
pubmed: 34025664
pmcid: 8134682
doi: 10.3389/fimmu.2021.663495
Sun X, Wu B, Chiang HC, Deng H, Zhang X, Xiong W, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 2021;599:673–8.
pubmed: 34732895
pmcid: 8839149
doi: 10.1038/s41586-021-04057-2
Moser M, Legate KR, Zent R, Fässler R. The tail of integrins, talin, and kindlins. Science. 2009;324:895–9.
pubmed: 19443776
doi: 10.1126/science.1163865
Calderwood DA, Campbell ID, Critchley DR. Talins and kindlins: partners in integrin-mediated adhesion. Nat Rev Mol Cell Biol. 2013;14:503–17.
pubmed: 23860236
pmcid: 4116690
doi: 10.1038/nrm3624
Kadry YA, Maisuria EM, Huet-Calderwood C, Calderwood DA. Differences in self-association between kindlin-2 and kindlin-3 are associated with differential integrin binding. J Biol Chem. 2020;295:11161–73.
pubmed: 32546480
pmcid: 7415974
doi: 10.1074/jbc.RA120.013618
Kuijpers TW, van de Vijver E, Weterman MAJ, de Boer M, Tool ATJ, van den Berg TK, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood. 2009;113:4740–6.
pubmed: 19064721
doi: 10.1182/blood-2008-10-182154
Svensson L, Howarth K, McDowall A, Patzak I, Evans R, Ussar S, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med. 2009;15:306–12.
pubmed: 19234463
pmcid: 2680140
doi: 10.1038/nm.1931
Bialkowska K, Sossey-Alaoui K, Pluskota E, Izem L, Qin J, Plow EF. Site-specific phosphorylation regulates the functions of kindlin-3 in a variety of cells. Life Sci Alliance. 2019;3:e201900594.
pubmed: 32024667
doi: 10.26508/lsa.201900594
Tang Y, Nan N, Gui C, Zhou X, Jiang W, Zhou X. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signaling regulates chemoresistance and immune evasion of colorectal cancer cells. Clin Exp Pharm Physiol. 2022;49:988–97.
doi: 10.1111/1440-1681.13685
Su X, Liu N, Wu W, Zhu Z, Xu Y, He F, et al. Comprehensive analysis of prognostic value and immune infiltration of kindlin family members in non-small cell lung cancer. BMC Med Genomics. 2021;14:119.
pubmed: 33934696
pmcid: 8091749
doi: 10.1186/s12920-021-00967-2
Djaafri I, Khayati F, Menashi S, Tost J, Podgorniak MP, Sadoux A, et al. A novel tumor suppressor function of Kindlin-3 in solid cancer. Oncotarget. 2014;5:8970–85.
pubmed: 25344860
pmcid: 4253411
doi: 10.18632/oncotarget.2125
Delyon J, Khayati F, Djaafri I, Podgorniak MP, Sadoux A, Setterblad N, et al. EMMPRIN regulates β1 integrin-mediated adhesion through Kindlin-3 in human melanoma cells. Exp Dermatol. 2015;24:443–8.
pubmed: 25807898
doi: 10.1111/exd.12693
Feng C, Wee WK, Chen H, Ong LT, Qu J, Tan HF, et al. Expression of kindlin-3 in melanoma cells impedes cell migration and metastasis. Cell Adhes Migr. 2017;11:419–33.
doi: 10.1080/19336918.2016.1243645
Bozdogan O, Guresci S, Öcalan D, Bozdogan N. Kindlin-3 and RASSF6 are probable biomarkers for predicting metastasis in cutaneous melanoma. Pol J Pathol J Pol Soc Pathol. 2021;72:237–44.
doi: 10.5114/pjp.2021.111774
Sossey-Alaoui K, Pluskota E, Davuluri G, Bialkowska K, Das M, Szpak D, et al. Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J Publ Fed Am Soc Exp Biol. 2014;28:2260–71.
Kato H, Honda S, Kashiwagi H, Nishiura N, Akuta K, Kokame K, et al. The critical role of kindlin-3 in intiation of physiological thrombus formation ~ analysis of kindlin-3 deficient patient. Blood. 2019;134:1062.
doi: 10.1182/blood-2019-129668
Kerr BA, Shi L, Jinnah AH, Harris KS, Willey JS, Lennon DP, et al. Kindlin-3 mutation in mesenchymal stem cells results in enhanced chondrogenesis. Exp Cell Res. 2021;399:112456–112456.
pubmed: 33417921
pmcid: 7874523
doi: 10.1016/j.yexcr.2020.112456
Hidalgo-Carcedo C, Hooper S, Chaudhry SI, Williamson P, Harrington K, Leitinger B, et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat Cell Biol. 2011;13:49–58.
pubmed: 21170030
doi: 10.1038/ncb2133
Ricard AS, Pain C, Daubos A, Ezzedine K, Lamrissi-Garcia I, Bibeyran A, et al. Study of CCN3 (NOV) and DDR1 in normal melanocytes and vitiligo skin. Exp Dermatol. 2012;21:411–6.
pubmed: 22507556
doi: 10.1111/j.1600-0625.2012.01473.x
Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012;31:295–321.
pubmed: 22366781
pmcid: 3351584
doi: 10.1007/s10555-012-9346-z
Moser M, Nieswandt B, Ussar S, Pozgajova M, Fässler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008;14:325–30.
pubmed: 18278053
doi: 10.1038/nm1722
Staudinger LA, Spano SJ, Lee W, Coelho N, Rajshankar D, Bendeck MP, et al. Interactions between the discoidin domain receptor 1 and β1 integrin regulate attachment to collagen. Biol Open. 2013;2:1148–59.
pubmed: 24244851
pmcid: 3828761
doi: 10.1242/bio.20135090
Xu H, Bihan D, Chang F, Huang PH, Farndale RW, Leitinger B. Discoidin domain receptors Promote α1β1- and α2β1-integrin mediated cell adhesion to collagen by enhancing integrin activation. PLOS ONE. 2012;7:e52209.
pubmed: 23284937
pmcid: 3527415
doi: 10.1371/journal.pone.0052209
Reger de Moura C, Battistella M, Sohail A, Caudron A, Feugeas JP, Podgorniak MP, et al. Discoidin domain receptors: A promising target in melanoma. Pigment Cell Melanoma Res. 2019;32:697–707.
pubmed: 31271515
doi: 10.1111/pcmr.12809
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102.
pubmed: 28407145
pmcid: 5570223
doi: 10.1093/nar/gkx247
Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep. 2008;10:439–46.
pubmed: 18706274
pmcid: 5662003
doi: 10.1007/s11912-008-0067-y
Gao Y, Zhou J, Li J. Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies. Cancer Sci. 2021;112:962–9.
pubmed: 33377205
pmcid: 7935774
doi: 10.1111/cas.14789
Kamohara H, Yamashiro S, Galligan C, Yoshimura T. Discoidin domain receptor 1 isoform-a (DDR1alpha) promotes migration of leukocytes in three-dimensional collagen lattices. FASEB J Publ Fed Am Soc Exp Biol 2001;15:2724–6.
Curat CA, Vogel WF. Discoidin domain receptor 1 controls growth and adhesion of mesangial cells. J Am Soc Nephrol JASN. 2002;13:2648–56.
pubmed: 12397034
doi: 10.1097/01.ASN.0000032419.13208.0C
Borza CM, Bolas G, Zhang X, Browning Monroe MB, Zhang MZ, Meiler J, et al. The Collagen Receptor Discoidin Domain Receptor 1b Enhances Integrin β1-Mediated Cell Migration by Interacting With Talin and Promoting Rac1 Activation. Front Cell Dev Biol. 2022;10:836797.
pubmed: 35309920
pmcid: 8928223
doi: 10.3389/fcell.2022.836797
Orré T, Joly A, Karatas Z, Kastberger B, Cabriel C, Böttcher RT, et al. Molecular motion and tridimensional nanoscale localization of kindlin control integrin activation in focal adhesions. Nat Commun. 2021;12:3104.
pubmed: 34035280
pmcid: 8149821
doi: 10.1038/s41467-021-23372-w
Shibue T, Weinberg RA. Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci. 2009;106:10290–5.
pubmed: 19502425
pmcid: 2700942
doi: 10.1073/pnas.0904227106
Fu W, Hall JE, Schaller MD. Focal adhesion kinase-regulated signaling events in human cancer. Biomol Concepts. 2012;3:225–40.
pubmed: 25436535
doi: 10.1515/bmc-2011-0049
Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. 2016;7:31586–601.
pubmed: 26980710
pmcid: 5058780
doi: 10.18632/oncotarget.8040
Berestjuk I, Lecacheur M, Carminati A, Diazzi S, Rovera C, Prod’homme V, et al. Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma. EMBO Mol Med [Internet]. févr 2022;14. Disponible sur: https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/34957688/ .
Sala M, Allain N, Moreau M, Jabouille A, Henriet E, Abou-Hammoud A, et al. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. Disponible sur: https://doi.org/10.1038/s41388-022-02266-1 .
Bayer SV, Grither WR, Brenot A, Hwang PY, Barcus CE, Ernst M, et al. DDR2 controls breast tumor stiffness and metastasis by regulating integrin mediated mechanotransduction in CAFs. eLife. 2019;8:e45508.
pubmed: 31144616
pmcid: 6555593
doi: 10.7554/eLife.45508
Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 2013;8:2145–50.
pubmed: 23899692
pmcid: 3800496
doi: 10.1021/cb400430t
Wang H, Wen Y, Wang L, Wang J, Chen H, Chen J, et al. DDR1 activation in macrophage promotes IPF by regulating NLRP3 inflammasome and macrophage reaction. Int Immunopharmacol. 2022;113:109294.
pubmed: 36257259
doi: 10.1016/j.intimp.2022.109294
Kobelt D, Walther W, Stein US. Real-time cell migration monitoring to analyze drug synergism in the scratch assay using the IncuCyte System. Methods Mol Biol Clifton NJ. 2021;2294:133–42.
doi: 10.1007/978-1-0716-1350-4_9